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ABSTRACT 
INTRODUCTION: The main factors in the development of ST-segment elevation myocardial infarction (STEMI) 
are inflammatory processes and pathophysiological changes due to oxidant stress. The aim of this study is to 
evaluate the association of prevalent STEMI with markers of inflammatory and oxidative stress. The platelet 
to monocyte ratio (PMR) was evaluated as a new hematological inflammatory marker.
MATERIAL AND METHODS: The study is a retrospective observational study conducted in the emergency 
department between January 2018 and January 2019. In the study, all patients who were diagnosed with 
STEMI were considered in the study group. Evaluations of inflammatory and oxidant stress markers, PMR 
value of STEMI patients were performed.
RESULTS: Neutrophil to lymphocyte ratio (NLR) value of 5.63 (3.35–7.84), Monocyte count to high-density 
lipoprotein cholesterol ratio (MHR) value of 16.10 (12.73–19.52), gamma-glutamyl transferase (GGT) value 
of 31.00 (21–39) and CRP value of 5.10 (2.77–9.34) were significantly higher in STEMI cases (p < 0.005). The 
lymphocyte to monocyte ratio (LMR) value of 2.57 (2.00–3.61) and the PMR value of 24.52 ± 7.60 in STEMI 
cases were significantly lower (p < 0.001, p = 0.014). 
CONCLUSIONS: In STEMI patients NLR, GGT, and MHR rates increase significantly and LMR decreases. PMR 
values were also lower in STEMI cases. This shows us that PMR is a new determinant that can be used in 
inflammatory events. However, none of these inflammatory markers and oxidant stress markers can be used 
as diagnostic tests, rather they should be considered as surrogate markers for disease.
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INTRODUCTION
ST-segment elevation myocardial infarction (STEMI) 
manifests as acute thrombotic coronary artery occlusion 
caused by atherosclerotic plaque rupture, plaque ero-
sion or calcific plaque and is the leading cause of death 
worldwide [1, 2]. The main factors in the develop-
ment of this condition are inflammatory processes and 
pathophysiological changes due to oxidant stress [3]. 
Many complete blood count (CBC) parame-
ters are useful predictive markers in cardiovascular 
events [4]. The increase in the neutrophil to lym-
phocyte ratio (NLR), the increase in monocyte count, 
the decrease in lymphocyte count and as a result the 
decrease in the lymphocyte to monocyte ratio (LMR), 
are considered indicative hematological biomarkers 
of inflammatory processes. At the same time, these 
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markers are accepted as predictors both of the se-
verity of the disease and the prognosis in coronary 
procedures for atherosclerotic diseases [5]. Gam-
ma-glutamyl transferase (GGT) plays a role in the 
transport of glutathione, which in turn plays a role 
in intracellular antioxidant mechanisms. GGT levels 
increase in the case of an acute coronary syndrome 
such as atherosclerosis induced by oxidant stress 
[6]. High-density lipoprotein cholesterol (HDL-C) 
has a protective role against inflammation, oxidant 
stress and thrombus development. Monocytes are 
known to play a role in the development of athero-
sclerotic plaque [7]. Monocyte count to high-density 
lipoprotein cholesterol ratio (MHR) has been report-
ed to increase in serious cardiovascular events as 
a result of the development of atherosclerosis [8]. 
The aim of this study was to evaluate the STEMI 
status in which inflammation and oxidant stress play 
a role together with factors such as NLR (which is an 
inflammatory marker) and GGT and MHR (which are 
oxidant stress markers). In addition, the platelet to 
monocyte ratio (PMR) was evaluated as a new he-
matological inflammatory marker in STEMI patients.
MATERIAL AND METHODS
Study design and population
The study is a retrospective observational study 
conducted in the emergency department of Bo-
zok University Faculty of Medicine between January 
2018 and January 2019. The methodology of the 
study was in accordance with the protocol approved 
by the University Local Ethics Committee. 
All patients who were admitted to the emergen-
cy department with chest pain and were diagnosed 
with STEMI or referred from the external center 
with the diagnosis of STEMI and whose blood was 
taken on arrival were considered for the study. All 
data were obtained by examining patients’ files, 
electronic records in the hospital information sys-
tem and angiography reports. STEMI was diag-
nosed by the presence of ST-segment elevation in at 
least two consecutive leads in electrocardiography 
(ECG), which was taken from patients with per-
sistent chest pain or other suggestive symptoms 
of ischemia. STEMI diagnoses were confirmed by 
angio reports. There were 134 patients admitted 
with STEMI during the study period. The following 
patients (n = 48) were excluded from the study: 
those under the age of 18, patients that had con-
sumed alcohol, those with chronic liver function 
impairment or chronic liver disease (both of which 
can affect the GGT levels), patients with deep vein 
thrombosis, peripheral arterial disease, diabetes mel-
litus, metabolic syndrome, heart failure, rheumat-
ic diseases, inflammatory bowel diseases, thyroid 
diseases and inflammatory diseases (which affect 
hematological inflammatory parameters), sufferers 
of familial hypercholesterolemia (which affects the 
HDL-C), patients receiving anticoagulant and anti-
aggregant treatment (which may cause a change in 
platelet counts) and patients with inadequate data. 
The remaining STEMI patients [n = 86: 28 (32.6%) 
female; 58 (76.4%) male]. Healthy volunteers were 
included in the study as the control group, [n = 82: 
37 (44.6%) female; 45 (54.2%) male]. 
The following blood hematological parameters 
were examined from the first blood tests: hemo-
globin (Hb), hematocrit (Htc), leucocyte, monocyte, 
neutrophil, red blood cell distribution width (RDW), 
mean platelet volume (MPV), mean corpuscular he-
moglobin concentration (MCHC), platelet (Plt). GGT 
levels and lipid panels were also examined from the 
first blood samples. In addition, evaluations of NLR, 
LMR, platelet to lymphocyte ratio (PLR), PMR, MHR 
values of STEMI patients were performed.
Laboratory analysis
Tubes containing EDTA (Ethylenedinitrile-tetraacetic 
acid) were used for complete blood count (CBC) 
from all four groups. In order to prevent errors in 
platelet and other hematological parameters, sam-
ples were studied in the biochemistry laboratory 
with an XN-1000 hematology analyzer (Sysmex Cor-
poration, Kobe, Japan) within the first hour. Serum 
gel tubes were used for biochemical analysis before 
centrifugation. Measurements of GGT, C-reactive 
protein (CRP), HDL-C were performed on a Cobas 
6000 analyzer (Roche Diagnostics, Mannheim, Ger-
many). 
Statistical analysis
IBM SPSS Statistics for Windows version 23.0 (IBM, 
Armonk, NY, USA) was used for statistical analy-
sis. The Kolmogorov–Smirnov test was used as a test 
for normality of continuous data and the results 
were expressed as the median with 25th and 75th 
percentiles. A non-parametric Mann–Whitney U test 
was used to compare the medians between the 
two groups. ROC (receiver operating characteristic) 
analysis was performed to evaluate NLR, MHR, PLR, 
LMR and PMR for predicting disease status. The area 
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under the curve and the cut-off value were calcu-
lated for each value. Sensitivity, selectivity, positive 
predictive value and negative predictive value were 
calculated to evaluate the diagnostic test perfor-
mance of each score. The statistical significance level 
was accepted as p < 0.05.
RESULTS
Our study investigated the two groups: STEMI pa-
tients and the control group. The mean age of the 
STEMI group (n = 86) was 61 ± 13 years and 
the mean age of the control group (n = 82) was 
62 ± 12 years. In the STEMI group, 43 (50%) pa-
tients had inferior MI, 30 (34.9%) had anterior MI, 
1 (1.2%) had lateral MI, 3 (3.5%) had posterior MI, 
9 (10.5%) had multiple vascular involvement MI. 
Comparison of the groups
Table 1 shows the comparison of demographic data 
and laboratory parameters of the patient and control 
groups. NLR value of 5.63 (3.35–7.84), MHR value 
of 16.10 (12.73–19.52), GGT value of 31.00 (21–39) 
and CRP value of 5.10 (2.77–9.34) were significant-
ly higher in STEMI cases compared to the control 
group (p < 00.5). The LMR value of 2.57 (2.00–3.61) 
and the PMR value of 24.52 ± 7.60 in STEMI cases 
were significantly lower compared with the control 
group (p < 0.001, p = 0.014) (Fig. 1). When Hb, 
HCT, MCHC, PLT, HDL-C and PLR values were exam-
ined, no statistically significant difference was found 
between the two groups (p > 0.05).
ROC analysis
Table 2 shows the sensitivity, specificity, positive pre-
dictive values, negative predictive values and area 
under curve values of the patients and the control 
group according to ROC analysis. In the analysis, 
high GGT, MHR and NLR were found to be signif-
icant in favor of the disease (p < 0.001), whereas 
low LMR and PMR were found to be significant in 
favor of the disease (p < 0.001, p = 0.014). In Fig-
ure 2, ROC analysis graphs of GGT, NLR, MHR, PLR, 
LMR and PMR values are given.
DISCUSSION
Because both inflammatory processes and oxidant 
stress play an important role in the pathophysiology 
of acute coronary syndrome, blood parameters as-
sociated with these two conditions were examined 
together in this study. While NLR, GGT and MHR 





















































































Data were expressed as Mean ± SD and median (25%–75% interquartile range).
CRP — C-reactive protein; GGT — gamma-glutamyltransferase; Hb —hemoglobin; HDL-C — High density lipoprotein cholesterol (HDL-C); Htc — hematocrit; LMR — lymphocyte to 
monocyte ratio; MCHC — mean corpuscular hemoglobin concentration; MCV — main corpuscular volume; MHR — monosite to HDL-C; MPV — mean platelet volume; NLR — neutrophil 
to lymphocyte ratio; PLR — platelet to lymphocyte ratio; PLT — platelet; PMR — platelet to lymphocyte ratio; RDW — Red blood cell distribution width
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fIgURE 1. Relationship between parameters and disease
Table 2. Comparison of GGT, NLR, PLR, LMR, PMR values according to disease status
Variables
Statistical diagnostic measures ROC curve statistics












































AUC — Area under curve; CI — Confidence interval; GGT — gama-glutamyl transferase; LMR — lymphocyte to monocyte ratio; MHR — monosite to HDL-C; NLR — neutrophil to lym-
phocyte ratio; NPV — Negative predictive value; PLR — platelet to lymphocyte ratio; PMR — platelet to lymphocyte ratio; PPV — Positive predictive value; ROC — Receiver operating 
characteristic; SEN — Sensitivity; SPE — Specificity 
* a decrease in the value causes the disease
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fIgURE 2. Receiver operating characteristic curves of inflammatory parameters according to the presence of ST-elevation myocardial 
infarction
rates were found to be significant in terms of STEMI 
disease, low LMR and PMR values were also signifi-
cant in terms of disease. It has been determined that 
MHR cannot be used as a marker of disease, but it 
can be useful in terms of prognosis and guidance. 
In addition, low levels of PMR can be used as an 
inflammatory marker in STEMI cases.
NLR, PLR and LMR values are used as markers that 
determine the inflammatory response in many dis-
eases including in cancer cases such as CRP [9, 10]. 
In addition to elevated systemic inflammatory re-
sponse, high levels of NLR has been reported to be 
an independent risk factor for increased mortality 
and long-term poor prognosis in both acute cor-
onary syndrome and STEMI patients [11]. In our 
study, high levels of NLR support this information. 
In the evaluations for PLR, both platelet increase and 
lymphocyte decrease have been shown to be a poor 
prognosis predictor for coronary events. Azap et al. 
[10] found that PLR increase is a predictor of long-
term mortality in non-STEMI cases. In our study, 
although the PLR rates in STEMI cases were higher 
than the control group, no statistical significance 
was found. It has been emphasized in many studies 
that LMR, which is expected to decrease in cases 
of malignancy and viral infection, is a predictor of 
coronary slow flow in patients with coronary artery 
disease and has a negative correlation with both 
CRP and NLR [12–14]. Another study showed that 
increased platelet and monocyte activity was found 
to be the predictor of atherosclerosis in hemodialy-
sis patients and peritoneal dialysis patients [15]. In 
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a study on patients with chronic obstructive pulmo-
nary disease (COPD), platelet-monosyte interaction 
was found to have increased [16] but to our knowl-
edge, PMR has not been considered as an inflamma-
tory marker in any study including coronary artery 
disease. In patients with coronary artery disease, 
no change was reported in platelet levels unless 
antiaggregant treatment was used, but changes in 
platelet shape and volumetric measurements, such 
as MPV, were detected [17]. In our study, patients 
receiving anticoagulant and antiaggregant treat-
ment were excluded and no difference was found 
between STEMI cases and the control group in terms 
of platelet measurements. The ratio of platelets to 
monocytes as a result of inflammatory processes 
was found to be low in STEMI cases.
It has been shown that the level of GGT increases 
both in hepatobiliary system pathology and with 
alcohol use and is accepted as a marker for these 
conditions [18, 19]. In addition to being an oxidant 
stress biomarker [6], GGT was also found to be 
active in the oxidation of low-density lipoprotein 
(LDL) and the development of atheroma plaques 
in the coronary arteries [20]. Valjevac et al. [21] 
found a positive correlation between GGT and CRP 
in patients with the acute coronary syndrome. The 
GGT elevation in STEMI cases detected in our study 
confirms this finding.
Monocytes, macrophages and dendritic cell pre-
cursors play a key role in the development of ath-
erosclerosis. Circulating monocytes in patients with 
cardiovascular disease have a high level of surface 
receptors in the inflammatory response. Monocytes 
present in the inflammation area form a complex 
with oxidized LDL. This complex is described as 
a dendritic cell or inflammatory macrophage. These 
cells cause atherosclerosis by forming oily streaks 
or foam cells [22]. HDL-C has anti-inflammatory 
and antioxidant effects on endothelial functions, 
in particular, by interfering with or even reversing 
monocyte activation and adhesion [7]. A literature 
search in the light of this information showed that 
MHR is an independent risk factor for five-year mor-
tality in STEMI patients [8]. Demir et al. [23] found 
that MHR was elevated in patients with metabolic 
syndrome. This increase is due to decreasing HDL-C 
levels in metabolic syndrome. The antioxidant activi-
ty of HDL-C is well known [24]. We found that since 
there was no significant difference between HDL-C 
levels in STEMI patients and the control group, the 
elevation of MHR was independent of antioxidant 
mechanisms and due to the increase in monocytes 
as an inflammatory marker.
There are some limitations to our study. Firstly, 
it was a single-center study and therefore we had 
a limited number of patients. Secondly, our study 
was retrospective and based on files and electron-
ic records. Multi-center studies with larger patient 
groups are needed.
CONCLUSIONS
Previous studies have investigated hematological 
inflammatory markers and oxidant stress markers 
separately in STEMI cases. However, to the best of 
our knowledge, there has not been a study that 
examines all of these markers together. In STEMI 
patients NLR, GGT, and MHR rates increase signif-
icantly and LMR decreases. Cut off values for GGT 
and NLR show high sensitivity for the disease. In 
our study, PMR values were also lower in STEMI 
cases. This shows us that PMR is a new determinant 
that can be used in inflammatory events. However, 
none of these inflammatory markers and oxidant 
stress markers can be used as diagnostic tests, rath-
er they should be considered as surrogate markers 
for disease.
Conflict of interest: The authors have no conflict 
of interest to declare.
Declaration of interest: All authors disclose any 
financial and personal relationships with other 
people or organizations that could inappropriately 
influence their work.
Submission declaration: All authors declare that 
this paper is not published or under consideration 
for publishing elsewhere.
Journal policies: All authors reviewed in detail the 
journal policies.
Ethical conduct of research: The authors have 
obtained approval from the review board of the 
Bozok University Faculty of Medicine, decision 
number 2017-KAEK-189_2019.11.13_06.
RefeReNCes
1. Choudhury T, West NEj, El-Omar M. ST elevation myocardial infarction. 
Clin Med (Lond). 2016; 16(3): 277–282, doi: 10.7861/clinmedi-
cine.16-3-277, indexed in Pubmed: 27251920.
İbrahim Çaltekin, Erdal Demirtaş, Inflammatory markers in STEMI
211www.journals.viamedica.pl
2. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardi-
ovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016; 
14(5): 573–577, doi: 10.1586/14779072.2016.1154788, indexed 
in Pubmed: 26878164.
3. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative 
stress, and risk of cardiovascular events in patients with coronary 
artery disease. Circulation. 2001; 104(22): 2673–2678, doi: 10.1161/
hc4601.099485, indexed in Pubmed: 11723017.
4. Gunes H, Saritas A, Cangur S, et al. Complete Blood Count Parameters 
for Prediction of non-ST Segment Elevation Myocardial Infarction. 
J Coll Physicians Surg Pak. 2019; 29(8): 710–714, doi: 10.29271/
jcpsp.2019.08.710, indexed in Pubmed: 31358088.
5. Kiris T, Çelik A, Variş E, et al. Association of Lymphocyte-to-Monocyte 
Ratio With the Mortality in Patients With ST-Elevation Myocardial In-
farction Who Underwent Primary Percutaneous Coronary Intervention. 
Angiology. 2017; 68(8): 707–715, doi: 10.1177/0003319716685480, 
indexed in Pubmed: 28056530.
6. Gul M, Uyarel H, Ergelen M, et al. The relationship between γ-glu-
tamyl transferase levels and the clinical outcomes in patients with 
ST-segment elevation myocardial infarction undergoing primary 
percutaneous coronary intervention. Coron Artery Dis. 2013; 24(4): 
272–278, doi: 10.1097/MCA.0b013e328360d131, indexed in Pu-
bmed: 23542158.
7. Arısoy A, Altunkaş F, Karaman K, et al. Association of the Monocyte 
to HDL Cholesterol Ratio With Thrombus Burden in Patients With 
ST-Segment Elevation Myocardial Infarction. Clin Appl Thromb Hemost. 
2017; 23(8): 992–997, doi: 10.1177/1076029616663850, indexed 
in Pubmed: 27534422.
8. Açıkgöz SK, Açıkgöz E, Şensoy B, et al. Monocyte to high-density 
lipoprotein cholesterol ratio is predictive of in-hospital and five-year 
mortality in ST-segment elevation myocardial infarction. Cardiol J. 
2016; 23(5): 505–512, doi: 10.5603/CJ.a2016.0026, indexed in 
Pubmed: 27296159.
9. Lee SM, Russell A, Hellawell G. Predictive value of pretreatment in-
flammation-based prognostic scores (neutrophil-to-lymphocyte ratio, 
platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for 
invasive bladder carcinoma. Korean J Urol. 2015; 56(11): 749–755, 
doi: 10.4111/kju.2015.56.11.749, indexed in Pubmed: 26568792.
10. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio 
as a predictor of all-cause mortality after non-ST-elevation myocar-
dial infarction. J Thromb Thrombolysis. 2012; 34(3): 326–334, doi: 
10.1007/s11239-012-0718-6, indexed in Pubmed: 22466812.
11. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte 
ratio to coronary flow to in-hospital major adverse cardiac events in 
patients with ST-elevated myocardial infarction undergoing primary 
coronary intervention. Am J Cardiol. 2012; 110(5): 621–627, doi: 
10.1016/j.amjcard.2012.04.041, indexed in Pubmed: 22608360.
12. Yayla Ç, Akboğa MK, Gayretli Yayla K, et al. A novel marker of inflam-
mation in patients with slow coronary flow: lymphocyte-to-monocyte 
ratio. Biomark Med. 2016; 10(5): 485–493, doi: 10.2217/bmm-2016-
0022, indexed in Pubmed: 27089433.
13. Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte 
to monocyte ratio predicts clinical outcome in patients with stage 
III colon cancer. Br J Cancer. 2014; 110(2): 435–440, doi: 10.1038/
bjc.2013.785, indexed in Pubmed: 24357796.
14. Merekoulias G, Alexopoulos EC, Belezos T, et al. Lymphocyte to mono-
cyte ratio as a screening tool for influenza. PLoS Curr. 2010; 2: RRN1154, 
doi: 10.1371/currents.rrn1154, indexed in Pubmed: 20383263.
15. Stach K, Karb S, Akin I, et al. Elevation of Platelet and Monocyte Activity 
Markers of Atherosclerosis in Haemodialysis Patients Compared to 
Peritoneal Dialysis Patients. Mediators Inflamm. 2017; 2017: 8506072, 
doi: 10.1155/2017/8506072, indexed in Pubmed: 28769539.
16. Aleva FE, Temba G, de Mast Q, et al. Increased Platelet-Monocyte 
Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity. 
Respiration. 2018; 95(1): 35–43, doi: 10.1159/000480457, indexed 
in Pubmed: 29020675.
17. Khode V, Sindhur J, Kanbur D, et al. Mean platelet volume and other 
platelet volume indices in patients with stable coronary artery disease 
and acute myocardial infarction: A case control study. J Cardiovasc Dis 
Res. 2012; 3(4): 272–275, doi: 10.4103/0975-3583.102694, indexed 
in Pubmed: 23233769.
18. Jiang S, Jiang D, Tao Y. Role of gamma-glutamyltransferase in 
cardiovascular diseases. Exp Clin Cardiol. 2013;18(1):53-6. PMID: 
24294039; PMCID. : PMC3716505.
19. Kim JG, Chang K, Choo EHo, et al. Serum gamma-glutamyl trans-
ferase is a predictor of mortality in patients with acute myocardial 
infarction. Medicine (Baltimore). 2018; 97(29): e11393, doi: 10.1097/
MD.0000000000011393, indexed in Pubmed: 30024510.
20. Emdin M, Passino C, Michelassi C, et al. Prognostic value of serum 
gamma-glutamyl transferase activity after myocardial infarction. Eur 
Heart J. 2001; 22(19): 1802–1807, doi: 10.1053/euhj.2001.2807, 
indexed in Pubmed: 11549302.
21. Valjevac A, Rebic D, Hamzic-Mehmedbasic A, et al. The value of 
gamma glutamyltransferase in predicting myocardial infarction in 
patients with acute coronary syndrome. Future Cardiol. 2018; 14(1): 
37–45, doi: 10.2217/fca-2017-0033, indexed in Pubmed: 29199860.
22. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during 
atherogenesis. Arterioscler Thromb Vasc Biol. 2011; 31(7): 1506–1516, 
doi: 10.1161/ATVBAHA.110.221127, indexed in Pubmed: 21677293.
23. Vahit D, Akboga MK, Samet Y, et al. Assessment of monocyte to high 
density lipoprotein cholesterol ratio and lymphocyte-to-monocyte ratio 
in patients with metabolic syndrome. Biomark Med. 2017; 11(7): 535–
540, doi: 10.2217/bmm-2016-0380, indexed in Pubmed: 28685581.
24. Escolà-Gil JC, Rotllan N, Julve J, et al. In vivo macrophage-specific RCT 
and antioxidant and antiinflammatory HDL activity measurements: 
New tools for predicting HDL atheroprotection. Atherosclerosis. 
2009; 206(2): 321–327, doi: 10.1016/j.atherosclerosis.2008.12.044, 
indexed in Pubmed: 19362310.
